ABC | Volume 115, Nº1, July 2020

Original Article Oliveira-Junior et al Effects of losartan in obesity Arq Bras Cardiol. 2020; 115(1):17-28 Table 2 – Mean and standard deviation of systolic blood pressure, measures of structure and functional performance of the heart analyzed by echocardiogram and left ventricular tissue Doppler, according to group and time of assessment Variable Moment Group CO OB CL OL SBP (mmHg) 16th Wks 119.4 ± 9.2 133.3 ± 12.3 * 119.5 ± 9.4 132.0 ± 9.6 ‡ 20th Wks 129.6 ± 9.3 139.3 ± 12.6 103.0 ± 13.2 * § 107.7 ± 7.4 † § HR (bpm) 16th Wks 277 ± 41 272 ± 27 276 ± 48 273 ± 44 20th Wks 285 ± 32 266 ± 39 265 ± 39 277 ± 39 LA (mm) 16th Wks 5.47 ± 0.79 5.80 ± 0.60 5.87 ± 0.74 5.81 ± 0.89 20th Wks 5.69 ± 0.56 5.95 ± 0.55 5.70 ± 0.60 5.77 ± 0.67 LA/AO 16th Wks 1.37 ± 0.18 1.45 ± 0.14 1.48 ± 0.14 1.42 ± 0.18 20th Wks 1.42 ± 0.16 1.44 ± 0.10 1.40 ± 0.11 1.42 ± 0.12 LVDT (mm) 16th Wks 1.317 ± 0.072 1.374 ± 0.044 1.313 ± 0.071 1.361 ± 0.058 20th Wks 1.272 ± 0.067 § 1.305 ± 0.043 § 1.262 ± 0.085 § 1.271 ± 0.061 § LVDD (mm) 16th Wks 7.95 ± 0.64 7.91 ± 0.37 7.80 ± 0.57 7.82 ± 0.44 20th Wks 8.11 ± 0.41 8.15 ± 0.26 8.06 ± 0.54 8.08 ± 0.52 LVDD/ Tibia (mm/mm) 16th Wks 0.184 ± 0.015 0.180 ± 0.008 0.182 ± 0.012 0.180 ± 0.007 20th Wks 0.188 ± 0.010 0.186 ± 0.007 0.188 ± 0.011 0.187 ± 0.012 LVSD (mm) 16th Wks 3.65 ± 0.68 3.56 ± 0.39 3.54 ± 0.65 3.69 ± 0.56 20th Wks 3.66 ± 0.42 3.55 ± 0.50 3.86 ± 0.67 3.75 ± 0.62 PWSV (mm/s) 16th Wks 40.44 ± 4.70 43.63 ± 2.95 42.31 ± 5.11 39.29 ± 3.96 20th Wks 42.92 ± 4.45 48.72 ± 4.81 * § 42.82 ± 3.60 47.96 ± 4.03 ‡ § EF 16th Wks 0.900 ± 0.039 0.907 ± 0.023 0.903 ± 0.037 0.892 ± 0.037 20th Wks 0.907 ± 0.022 0.914 ± 0.033 0.887 ± 0.039 0.898 ± 0.037 ES (%) 16th Wks 54.32 ± 6.38 55.00 ± 3.72 54.83 ± 6.28 52.92 ± 5.41 20th Wks 54.94 ± 3.58 56.49 ± 5.67 52.34 ± 5.73 53.83 ± 5.45 E/A 16th Wks 1.65 ± 0.35 1.49 ± 0.25 1.52 ± 0.25 1.43 ± 0.23 20th Wks 1.60 ± 0.33 1.50 ± 0.23 1.74 ± 0.27 1.39 ± 0.26 ‡ EDT (ms) 16th Wks 50.09 ± 6.85 49.50 ± 4.56 47.64 ± 8.69 51.10 ± 6.19 20th Wks 47.64 ± 7.47 50.58 ± 6.59 50.17 ± 5.84 54.40 ± 5.77 IVRT 16th Wks 58.88 ± 6.98 58.12 ± 4.22 55.38 ± 7.72 54.66 ± 5.26 20th Wks 53.60 ± 4.22 52.47 ± 4.87 53.49 ± 7.17 52.72 ± 3.78 S’(cm/s) 16th Wks 3.57 ± 0.31 3.79 ± 0.28 3.72 ± 0.24 3.79 ± 0.45 20th Wks 4.00 ± 0.24 § 4.05 ± 0.47 3.91 ± 0.29 4.19 ± 0.27 § E’ (cm/s) 16th Wks 4.62 ± 0.53 4.23 ± 0.40 4.25 ± 0.39 4.04 ± 0.53 20th Wks 4.85 ± 0.57 4.80 ± 0.32 § 4.83 ± 0.38 § 4.92 ± 0.52 § A’ (cm/s) 16th Wks 3.75 ± 0.86 3.85 ± 0.59 3.78 ± 0.83 3.49 ± 0.50 20th Wks 4.37 ± 0.87 3.78 ± 1.08 3.61 ± 0.75 * 4.31 ± 0.81 § E/E’ 16th Wks 16.80 ± 3.62 18.76 ± 3.13 18.12 ± 2.27 18.86 ± 2.61 20th Wks 17.89 ± 2.59 18.79 ± 2.35 17.27 ± 1.52 17.22 ± 2.51 SBP: systolic blood pressure; HR: heart rate; LA / AO: relationship between the diameters of the left atrium (LA) and the aortic artery (AO); LVDT: diastolic thickness of the posterior wall; LVDD: left ventricular diastolic diameter; LVSD: left ventricular systolic diameter; PWSV: posterior wall shortening velocity; EF: ejection fraction; ES: endocardial shortening; E / A: relationship between the E and A waves of the transmitral flow; IVRT: isovolumetric relaxation time; EDT: E wave deceleration time; S ‘: systolic velocity of the mitral valve ring at tissue Doppler (TDI); E ‘: TDI of the diastolic velocity of the mitral valve ring (mean between septal and lateral walls); A ‘: TDI of the late diastolic velocity of the mitral valve ring (mean of the septal and lateral walls); E / E ‘: relation obtained between the velocities of the initial mitral valve flow and the TDI of the mitral valve ring; CO: Control group; OB: Obese group; CL: Control Losartan group; OL: Obese Losartan group. Group’s effects: * p <0.05 compared to CO; † p <0.05 compared to OB; ‡ p <0.05 compared to CL; Moment’s effect: § p <0.05 compared to the 16th week (Wks); Two-Way RMANOVA and Bonferroni test. 21